Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Bal Pharma Ltd

About the Company - Bal Pharma Ltd

Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 280.37 Cr. and Equity Capital is Rs. 14.82 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals# 21 & 22, Bommasandra Industrial Area, Bengaluru Karnataka 560099info@balpharma.com
http://www.balpharma.com
Management
NamePosition Held
Mr. Shailesh D SiroyaManaging Director
Mr. Himesh VirupakshayaExecutive Director
Mr. Jatish ShethIndependent Director
Dr. C V SrinivasIndependent Director
Ms. Nicloa NeeladriIndependent Director
Mr. H S VenkateshIndependent Director
Mr. Kotian Chittananda DamodarExecutive Director

Basic Stock Data of Bal Pharma Ltd

Last Updated: April 6, 2024, 5:47 am

Market Cap 158 Cr.
Current Price 100
High / Low132/69.5
Stock P/E45.5
Book Value 40.0
Dividend Yield1.00 %
ROCE9.56 %
ROE4.20 %
Face Value 10.0
PEG Ratio0.74

Bal Pharma Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales63.0370.8170.8367.1769.1774.0569.8475.3176.6282.4570.3992.5481.66
Expenses57.1064.4763.3560.8462.9570.6064.8069.5370.4774.2963.9584.8473.87
Operating Profit5.936.347.486.336.223.455.045.786.158.166.447.707.79
OPM %9.41%8.95%10.56%9.42%8.99%4.66%7.22%7.67%8.03%9.90%9.15%8.32%9.54%
Other Income0.190.730.140.560.753.700.240.050.460.190.160.140.10
Interest2.893.112.972.632.362.452.372.863.113.853.643.823.66
Depreciation2.033.442.192.212.212.422.232.372.452.092.532.422.96
Profit before tax1.200.522.462.052.402.280.680.601.052.410.431.601.27
Tax %66.67%-576.92%32.93%31.71%80.42%3.95%58.82%78.33%43.81%32.78%79.07%39.38%33.07%
Net Profit0.403.531.651.390.482.190.280.120.591.620.090.970.85
EPS in Rs0.232.421.090.930.431.330.180.070.361.020.050.610.56

Last Updated: May 11, 2024, 11:26 am

Bal Pharma Ltd Quarterly Chart

Bal Pharma Ltd Profit & Loss

MonthMar 2010Mar 2011Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales106114179187198229211225171251281304305
Expenses103104161170183214194207166226257279278
Operating Profit310181715151718525242527
OPM %3%9%10%9%7%6%8%8%3%10%9%8%9%
Other Income5111132121511
Interest6777689131312111213
Depreciation33577676810999
Profit before tax-1175333-0-144954
Tax %-57%60%23%25%90%114%87%1,175%5%-15%38%45%
Net Profit-10541-002-135632
EPS in Rs-1.360.394.562.821.101.241.962.67-8.623.203.781.641.50
Dividend Payout %0%0%22%35%91%81%51%37%0%31%26%61%

Bal Pharma Ltd Profit & Loss Yearly Chart

Bal Pharma Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:8%
3 Years:21%
TTM:11%
Compounded Profit Growth
10 Years:%
5 Years:47%
3 Years:30%
TTM:19%
Stock Price CAGR
10 Years:13%
5 Years:8%
3 Years:-3%
1 Year:16%
Return on Equity
10 Years:%
5 Years:1%
3 Years:7%
Last Year:4%

Last Updated: April 6, 2024, 5:47 am

Bal Pharma Ltd Balance Sheet

MonthMar 2010Mar 2011Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital10101113131414141415151616
Reserves25263740404851523839434848
Borrowings545851498993110124118110104131141
Other Liabilities3441566169788671687699116126
Total Liabilities124135155164211233260261238240261311330
Fixed Assets50485552566071707169677676
CWIP0001420430200
Investments0000000000000
Other Assets748799111151172188187164172192235254
Total Assets124135155164211233260261238240261311330

Bal Pharma Ltd Reserves and Borrowings Chart

Bal Pharma Ltd Cash Flow

MonthMar 2010Mar 2011Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity -551315-19618232227-2
Cash from Investing Activity 5-2-7-5-14-8-4-8-5-6-9-22
Cash from Financing Activity 1-2-8-732-640-20-17-1724
Net Cash Flow01-22-1-81-0-2000

Bal Pharma Ltd Financial Efficiency Indicators

MonthMar 2010Mar 2011Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days1101189388105991111051069898113
Inventory Days174191122132145172240217292146162207
Days Payable129157129142163171182147167114143167
Cash Conversion Cycle155153867887100168175231130117153
Working Capital Days1371419892142140163166180129109134
ROCE %4%8%11%7%8%8%7%-0%10%12%10%

Bal Pharma Ltd Financial Efficiency Indicators Chart

Bal Pharma Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters44.98%44.84%46.87%49.57%49.57%52.00%52.00%51.61%51.61%51.61%51.61%51.24%
FIIs0.00%0.00%0.15%0.31%0.31%0.30%0.20%0.18%0.17%0.17%0.14%0.13%
Public55.02%55.16%52.98%50.12%50.12%47.71%47.80%48.21%48.23%48.23%48.25%48.64%
No. of Shareholders12,64816,53116,31916,04916,22316,31716,17016,46616,02915,86915,52915,060

Bal Pharma Ltd Shareholding Pattern Chart

No. of Bal Pharma Ltd Shareholders

This stock is not held by any mutual fund

Bal Pharma Ltd ROCE Trend

Bal Pharma Ltd EPS Trend

Bal Pharma Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)1.673.793.34-9.101.52
Diluted EPS (Rs.)1.683.793.34-9.101.52
Cash EPS (Rs.)7.499.959.60-3.685.86
Book Value[Excl.RevalReserv]/Share (Rs.)40.6039.4635.9931.9942.49
Book Value[Incl.RevalReserv]/Share (Rs.)40.6039.4635.9931.9942.49
Revenue From Operations / Share (Rs.)193.89189.72169.02120.72158.77
PBDIT / Share (Rs.)16.6119.3117.274.6613.06
PBIT / Share (Rs.)10.7913.2110.85-0.758.72
PBT / Share (Rs.)3.036.202.77-9.55-0.14
Net Profit / Share (Rs.)1.673.853.18-9.101.52
NP After MI And SOA / Share (Rs.)1.643.793.20-8.622.67
PBDIT Margin (%)8.5610.1810.213.858.22
PBIT Margin (%)5.566.966.41-0.625.49
PBT Margin (%)1.563.261.63-7.90-0.08
Net Profit Margin (%)0.862.021.88-7.530.95
NP After MI And SOA Margin (%)0.841.991.89-7.141.68
Return on Networth / Equity (%)4.039.578.85-23.305.68
Return on Capital Employeed (%)16.3020.6418.36-1.3612.60
Return On Assets (%)0.822.151.97-5.121.44
Long Term Debt / Equity (X)0.470.460.440.440.43
Total Debt / Equity (X)2.051.671.952.151.74
Asset Turnover Ratio (%)1.011.060.990.680.86
Current Ratio (X)1.091.111.081.011.11
Quick Ratio (X)0.620.660.680.580.68
Inventory Turnover Ratio (X)2.082.432.121.051.67
Dividend Payout Ratio (NP) (%)0.0026.410.00-11.590.00
Dividend Payout Ratio (CP) (%)0.0010.110.00-31.210.00
Earning Retention Ratio (%)0.0073.590.00111.590.00
Cash Earning Retention Ratio (%)0.0089.890.00131.210.00
Interest Coverage Ratio (X)2.142.752.140.531.47
Interest Coverage Ratio (Post Tax) (X)1.211.551.39-0.031.17
Enterprise Value (Cr.)228.31252.09180.34148.68205.00
EV / Net Operating Revenue (X)0.750.890.710.860.91
EV / EBITDA (X)8.768.817.0522.5311.07
MarketCap / Net Operating Revenue (X)0.340.560.310.260.44
Retention Ratios (%)0.0073.580.00111.590.00
Price / BV (X)1.652.731.490.871.50
Price / Net Operating Revenue (X)0.340.560.310.260.44
EarningsYield0.020.030.05-0.260.03

Bal Pharma Ltd Profitability Ratios (%)

Bal Pharma Ltd Liquidity Ratios

Bal Pharma Ltd Liquidity Ratios (%)

Bal Pharma Ltd Interest Coverage Ratios (%)

Bal Pharma Ltd Valuation Ratios

Fair Value

Fair Value: ₹77.20

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 22.80% compared to the current price ₹100

Intrinsic Value: ₹124.99

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 24.99% compared to the current price ₹100

Last 5 Year EPS CAGR: 61.89%

*Investments are subject to market risks

Strength and Weakness of Bal Pharma Ltd Stock

StrengthWeakness
  1. The company has shown consistent growth in sales (212.38 cr) and profit (2.23 cr) over the years.
  1. The stock has a low average ROCE of 7.08%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 135.92, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 136.08, which may not be favorable.
  4. The company has higher borrowings (94.77) compared to reserves (41.15), which may suggest financial risk.

FAQ

What is the latest fair value of Bal Pharma Ltd?

The latest fair value of Bal Pharma Ltd is ₹77.20.

What is the Market Cap of Bal Pharma Ltd?

The Market Cap of Bal Pharma Ltd is 158 Cr..

What is the current Stock Price of Bal Pharma Ltd as on 06 April 2024?

The current stock price of Bal Pharma Ltd as on 06 April 2024 is 100.

What is the High / Low of Bal Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Bal Pharma Ltd stocks is ₹132/69.5.

What is the Stock P/E of Bal Pharma Ltd?

The Stock P/E of Bal Pharma Ltd is 45.5.

What is the Book Value of Bal Pharma Ltd?

The Book Value of Bal Pharma Ltd is 40.0.

What is the Dividend Yield of Bal Pharma Ltd?

The Dividend Yield of Bal Pharma Ltd is 1.00 %.

What is the ROCE of Bal Pharma Ltd?

The ROCE of Bal Pharma Ltd is 9.56 %.

What is the ROE of Bal Pharma Ltd?

The ROE of Bal Pharma Ltd is 4.20 %.

What is the Face Value of Bal Pharma Ltd?

The Face Value of Bal Pharma Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bal Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE